- Conditions
- Thyroid Nodule, Thyroid Cancer
- Interventions
- Thyroid Decision Aid
- Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 2
- States / cities
- Jacksonville, Florida • Rochester, Minnesota
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1273–1296
of 3,320
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Advanced Solid Tumors, MSI-H/dMMR Tumors, Cutaneous Squamous Cell Carcinoma, Urothelial Carcinoma, HCC, Cervical Cancer, Esophageal Squamous Cell Carcinoma, Merkel Cell Carcinoma, Small-cell Lung Cancer, Mesothelioma, PD-L1 Amplified Tumor (9p24.1), Nasopharyngeal Carcinoma, Cyclin-dependent Kinase 12 Mutated Tumors, Basal Cell Carcinoma (Unresectable or Metastatic), Sarcomatoid Renal Cell Carcinoma, Clear Cell Ovarian or Endometrial Carcinoma, Anal Carcinoma, Squamous Cell Penile Carcinoma, DNA Polymerase Epsilon Mutated Tumors (P286R and V411L)
- Interventions
- INCB099318
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 3
- States / cities
- Hackensack, New Jersey • Greenville, South Carolina • Nashville, Tennessee
- Conditions
- Urothelial Cancer, GastroEsophageal Cancer, Colorectal Cancer, Esophageal Cancer, Gastric Cancer (GC), Pancreatic Cancer
- Interventions
- MGC030
- Biological
- Lead sponsor
- MacroGenics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 314 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Lake Success, New York
- Conditions
- Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
- Interventions
- Durvalumab, Laboratory Biomarker Analysis, Stereotactic Body Radiation Therapy, Tremelimumab, Hypofractionated Image-Guided Radiation Therapy
- Biological · Other · Radiation + 1 more
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Brain and Nervous System, Intracranial Neoplasm, Head and Neck Cancer
- Interventions
- Computed Tomography, Medical Device, Cone-Beam Computed Tomography
- Procedure · Device
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Head and Neck Cancer
- Interventions
- Docetaxel, Stereotactic Radiation
- Drug · Radiation
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Salivary Gland Squamous Cell Carcinoma, Stage III Salivary Gland Cancer, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Nasopharynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IV Salivary Gland Cancer, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity
- Interventions
- PV701
- Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Thyroid Cancer
- Interventions
- IMRT, DWI MRI, Doxorubicin, Modified Barium Swallow Impairment Profile (MBSImP)
- Radiation · Device · Drug + 1 more
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2021
- U.S. locations
- 6
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 3 more
- Conditions
- Advanced Malignancy, Advanced Solid Tumors, Cancer, Oncology, Oncology Patients, Tumors, Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Transitional Cell Carinoma of Bladder, Colorectal Cancer
- Interventions
- AMG 228
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 3
- States / cities
- La Jolla, California • New Haven, Connecticut • New York, New York
- Conditions
- Papillary Thyroid Cancer
- Interventions
- percutaneous ethanol ablation
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Hearing Loss
- Interventions
- Normal Saline and 0.3% ofloxacin, Lactated Ringer's with 0.03% Ofloxacin
- Drug
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- Not interventional
- Other
- Lead sponsor
- New Mexico Cancer Research Alliance
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2023
- U.S. locations
- 1
- States / cities
- Albuquerque, New Mexico
- Conditions
- Squamous Cell Carcinoma of the Head and Neck
- Interventions
- Afatinib, Docetaxel, Radiation Therapy
- Drug · Radiation
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • New York, New York
- Conditions
- Esophageal Cancer
- Interventions
- erlotinib hydrochloride, immunohistochemistry staining method, radiation therapy
- Drug · Other · Radiation
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 65 Years to 120 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Squamous Cell Carcinoma of Mouth, Intraepithelial Neoplasia
- Interventions
- 10% FBR containing bioadhesive gel, placebo gel
- Drug
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 21 Years to 80 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 3
- States / cities
- Louisville, Kentucky • Chapel Hill, North Carolina • Columbus, Ohio
- Conditions
- Cancer of Head and Neck
- Interventions
- Metformin
- Drug
- Lead sponsor
- West Virginia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Morgantown, West Virginia
- Conditions
- Thyroid Cancer
- Interventions
- Radioactive Iodine 124
- Radiation
- Lead sponsor
- Medstar Health Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2018
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Carcinoma, Hepatocellular, Head and Neck Neoplasms, Gastrointestinal Neoplasms
- Interventions
- BI 765049, ezabenlimab
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Los Angeles, California • Orange, California + 9 more
- Conditions
- Neoplasms, Breast Neoplasms, Head and Neck Neoplasms
- Interventions
- BYL719, Paclitaxel
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 2
- States / cities
- Fayetteville, Arkansas • Lafayette, Indiana
- Conditions
- Esophageal Cancer
- Interventions
- cetuximab
- Biological
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2010
- U.S. locations
- 152
- States / cities
- Mobile, Alabama • Anchorage, Alaska • Little Rock, Arkansas + 104 more
- Conditions
- Recurrent Head and Neck Cancer, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Carcinoma, Metastatic Head-and-neck Squamous-cell Carcinoma, Metastatic Head and Neck Cancer, HNSCC
- Interventions
- Ramucirumab, Pembrolizumab
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- HEAD & NECK Cancer
- Interventions
- Cetuximab, IMRT, Albumin-bound paclitaxel (Abraxane®)
- Other
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2016
- U.S. locations
- 5
- States / cities
- Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
- Conditions
- Esophageal Cancer, Gastric Cancer, Adenocarcinoma
- Interventions
- Niraparib
- Drug
- Lead sponsor
- Shadia Jalal, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 4
- States / cities
- Tampa, Florida • Indianapolis, Indiana • Ann Arbor, Michigan + 1 more
- Conditions
- Esophageal Cancer, Gastric Cancer
- Interventions
- FOLFIRI regimen, fluorouracil, irinotecan hydrochloride, leucovorin calcium
- Drug
- Lead sponsor
- Robert H. Lurie Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Indianapolis, Indiana • Philadelphia, Pennsylvania + 1 more